REGION STOCKHOLM

Their core work

Region Stockholm is the public authority responsible for healthcare delivery across the Stockholm metropolitan area, operating major hospitals including Karolinska University Hospital. In H2020, they contribute real-world clinical infrastructure, patient cohorts, and healthcare system expertise to European research consortia — particularly in oncology, neurodegenerative diseases, rare diseases, and digital health. Their involvement typically brings large-scale clinical validation environments and health system implementation know-how that academic-only consortia lack.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), Region Stockholm focused heavily on neurodegenerative diseases (Alzheimer's, Parkinson's), rare conditions (osteogenesis imperfecta), and clinical screening programmes — reflecting a traditional academic hospital research profile. From 2019 onward, the focus shifted decisively toward data-driven medicine: omics-based stratification, patient empowerment platforms, risk-based screening, outcome measurement infrastructure, and pandemic response. This mirrors the broader European push toward precision medicine and value-based healthcare, but Region Stockholm's shift is notably strong in patient-reported outcomes and real-world data collection.

Region Stockholm is moving from disease-specific clinical trials toward building healthcare data infrastructure and patient outcome measurement systems — making them an increasingly valuable partner for digital health and precision medicine consortia.

How they like to work

Region Stockholm overwhelmingly participates as a consortium member or third party rather than leading projects — only 2 of 35 projects were coordinated, both in healthcare procurement/digital services. They operate in large consortia (551 unique partners across 42 countries), functioning as a clinical validation site and healthcare system testbed rather than a research driver. This makes them a reliable, low-friction partner who brings clinical infrastructure without competing for scientific leadership.

Exceptionally broad network of 551 unique partners across 42 countries, reflecting their role as a clinical site in large multi-centre consortia. Geographic reach spans all of Europe with strong IMI (Innovative Medicines Initiative) connections to pharma industry partners.

What sets them apart

Region Stockholm is not a university or research institute — it is the public body that actually runs healthcare for 2.4 million people in Sweden's capital region. This means they can offer what most research partners cannot: direct access to clinical populations, hospital infrastructure, electronic health records, and the ability to implement research findings into routine care. For any consortium that needs to demonstrate real-world clinical impact or validate digital health tools in a functioning hospital system, they are among the strongest partners in Northern Europe.

Highlights from their portfolio

• LIVE INCITE
  Their largest project (EUR 3.4M) and one of two they coordinated — a digital lifestyle intervention platform for perioperative care, showing their ambition to lead in digital health services.
• EJP RD
  European Joint Programme on Rare Diseases — a flagship infrastructure project covering data, omics, FAIR principles, and patient empowerment across rare disease research.
• H2O
  Health Outcomes Observatory — building pan-European patient-reported outcome infrastructure, central to the value-based healthcare movement they are increasingly focused on.